286 related articles for article (PubMed ID: 37302149)
1. P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
Fujisaki T; Kuno T; Briasoulis A; Misumida N; Takagi H; Latib A
Tex Heart Inst J; 2023 May; 50(3):. PubMed ID: 37302149
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of oral P2Y
Farmakis IT; Zafeiropoulos S; Doundoulakis I; Pagiantza A; Karagiannidis E; Moysidis DV; Stalikas N; Kassimis G; Michalis LK; Karvounis H; Giannakoulas G
Open Heart; 2022 Apr; 9(1):. PubMed ID: 35428703
[TBL] [Abstract][Full Text] [Related]
4. Meta-Analysis Comparing P2Y
Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
[TBL] [Abstract][Full Text] [Related]
5. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
[TBL] [Abstract][Full Text] [Related]
6. Impact of Society Guidelines on Trends in Use of Newer P2Y
Mohamed MO; Kontopantelis E; Alasnag M; Abid L; Banerjee A; Sharp ASP; Bourantas C; Sirker A; Curzen N; Mamas MA
J Am Heart Assoc; 2024 May; 13(9):e034414. PubMed ID: 38700032
[TBL] [Abstract][Full Text] [Related]
7. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
[TBL] [Abstract][Full Text] [Related]
8. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
10. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Wang Z; Zhou DY; Su Y; Si LY; Xu Q
BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
[TBL] [Abstract][Full Text] [Related]
11. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
12. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Aytekin A; Ndrepepa G; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Lahu S; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Valina C; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Fusaro M; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
Circulation; 2020 Dec; 142(24):2329-2337. PubMed ID: 33115278
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Valina C; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Aytekin A; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
J Am Coll Cardiol; 2020 Nov; 76(21):2436-2446. PubMed ID: 33213722
[TBL] [Abstract][Full Text] [Related]
14. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis.
Komosa A; Lesiak M; Krasiński Z; Grygier M; Siniawski A; Skorupski W; Olasińska-Wiśniewska A; Pyda M; Araszkiewicz A; Mitkowski P; Grajek S; Mularek-Kubzdela T; Hengstenberg C; Siller-Matula JM
Thromb Haemost; 2019 Jun; 119(6):1000-1020. PubMed ID: 30919382
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy and Safety of Oral P2Y
Navarese EP; Khan SU; Kołodziejczak M; Kubica J; Buccheri S; Cannon CP; Gurbel PA; De Servi S; Budaj A; Bartorelli A; Trabattoni D; Ohman EM; Wallentin L; Roe MT; James S
Circulation; 2020 Jul; 142(2):150-160. PubMed ID: 32468837
[TBL] [Abstract][Full Text] [Related]
16. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
Godtfredsen SJ; Kragholm KH; Leutscher P; Jørgensen SH; Christensen MK; Butt JH; Gislason G; Køber L; Fosbøl EL; Sessa M; Bhatt DL; Torp-Pedersen C; Pareek M
Eur Heart J Acute Cardiovasc Care; 2022 Sep; 11(9):697-705. PubMed ID: 35950769
[TBL] [Abstract][Full Text] [Related]
18. P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
Sachdeva A; Mutyala R; Mantri N; Zhu S; McNulty E; Solomon M
J Interv Cardiol; 2023; 2023():1147352. PubMed ID: 37251366
[TBL] [Abstract][Full Text] [Related]
19. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.
Hong J; Turgeon RD; Pearson GJ
Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764
[No Abstract] [Full Text] [Related]
20. Translation of experimental cardioprotective capability of P2Y
Hjortbak MV; Olesen KKW; Seefeldt JM; Lassen TR; Jensen RV; Perkins A; Dodd M; Clayton T; Yellon D; Hausenloy DJ; Bøtker HE;
Basic Res Cardiol; 2021 May; 116(1):36. PubMed ID: 34037861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
